Share the Science: What is best stem cell source for children with AML? Ask Dr. Heather Stefanski2/13/2023
Save the Cord Foundation and WellSky are proud to welcome Dr. Heather Stefanski as our featured speakers for the next edition of Share the Science on Tuesday, February 28th at 2pm US Eastern Time / 11am US Pacific Time. Join us to hear Dr. Heather Stefanski discuss how the source of stem cells influences outcomes for pediatric patients with Acute Myeloid Leukemia. Recording now available in the Share the Science Archive. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here. Treating children with AML: |
Heather Stefanski, MD, PhD Senior Vice President of Medical Services for Be The Match / National Marrow Donor Program Heather Stefanski, MD, PhD, understands the unique challenges transplant centers face. Before joining the National Marrow Donor Program® (NMDP)/Be The Match® as the Senior Vice President of Medical Services, she spent 27 years treating patients at the University of Minnesota (U of M) Division of Pediatric Blood and Marrow Transplant and Cellular Therapy. |
Share the Science and sharing her valuable insight
on the influence of cord blood stem cells in the treatment of AML in pediatric patients.
We also wish to also thank our generous sponsor and partner for this event,
WellSky Health, who continue to support cord blood
education through our “Share the Science” series.
Share the Science: Drs. Malhotra & Zhou - Potential Cord Blood Cell Therapy for Preterm Brain Injury
8/4/2022
RECORDING NOW AVAILABLE (watch via the Share the Science archive)
Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here.
Cell Therapy for Brain Injury:
What does the future hold?
For this edition of Share the Science, we are pleased to welcome both Dr. Atul Malhotra and Dr. Lindsay Zhou from Monash University who will discuss the potential of cord blood in the treatment of brain injury. In particular, they will discuss their own research in this area and a study to test the feasibility of collection and isolation of sufficient UCBCs from cord blood, and the safety of intravenous administration of autologous UCBCs in extremely preterm infants suffering from brain injury during the neonatal period.
Join us for this fascinating discussion with Dr. Atul Malhotra and Dr. Lindsay Zhou.
with
Dr. Atul Malhotra & Dr. Lindsay Zhou
Monash Children's Hospital, Department of Paediatrics,
Monash University - Melbourn, Australia
"Autologous Umbilical Cord Blood-Derived Cell
Administration in Extreme Preterm Infants"
Free webinar. Open to the public.
Wednesday, August 17th, 2022 5pm US Eastern Time / 4pm US Central Time
RECORDING NOW AVAILABLE
via the Share the Science Archive
About the speakers
Dr. Atul Malhotra Senior Consultant Neonatologist and Head of the Early Neurodevelopment Clinic at Monash Children's Hospital and Associate Professor (Research) & NHMRC Fellow in the Department of Paediatrics, Monash University. Associate Professor Atul Malhotra is a Senior Consultant Neonatologist and Head of the Early Neurodevelopment Clinic at Monash Children's Hospital and Associate Professor (Research) & NHMRC Fellow in the Department of Paediatrics, Monash University. He has published over 120 peer-reviewed journal articles, 4 book chapters and his research has attracted over $7.5 million of funding to date. He is also the co-Director of the Newborn Cell Therapies Group at Monash, which has been instrumental in the translation of preclinical therapies from the laboratory to the clinic, including regenerative cell therapies. He led a world-first trial of placental amnion epithelial cells for chronic lung disease of prematurity, and is the Principal Investigator of two cord blood derived cell therapy trials currently recruiting. |
Dr. Lindsay Zhou Consultant Neonatologist at Monash Children's Hospital and a PhD student at the Ritchie Centre and Department of Paediatrics, Monash University. Dr Lindsay Zhou is a Consultant Neonatologist at Monash Children's Hospital and a PhD student at the Ritchie Centre and Department of Paediatrics, Monash University. Dr. Zhou undertook his paediatric and neonatal training in Melbourne, and also works as a Retrieval Consultant at the Royal Children's Hospital Melbourne. His PhD studies focus on umbilical cord-blood derived cell therapy applications for extremely preterm infants. He is an Associate Investigator on the CordSaFe clinical trial, investigating the safety and feasibility of umbilical cord blood-derived cell collection and administration in infants born at less than 28 weeks. |
Share the Science and sharing their valuable insight
on the potential of using cord blood in cell therapy to treat preterm brain injury in enfants.
We also wish to also thank our generous sponsor and partner for this event,
WellSky Health, who continue to support cord blood
education through our “Share the Science” series.
Share the Science: Dr. Mitchell Horwitz - Improved Clinical Outcomes in Cord Blood Transplantation
6/13/2022
Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here.
Looking to the future of cord blood transplantation
In this spirit, Dr. Mitchell Horwitz and his team at Duke University Medical Center have led the way in new and pioneering cord blood research. Recently, the team published their encouraging results from a phase 3 randomized study on the efficacy of omidubicel vs. standards myeloablative umbilical cord blood transplantation. Omidubicel is an ex vivo expanded hematopoietic progenitor cell and non-expanded myeloid and lymphoid cell product that is derived from a single umbilical cord blood unit.
As part of Dr. Horwitz' study, between January 2017 and January 2020, 125 patients ages 13 to 65 years with hematologic malignancies were randomly assigned to this study. Patients received myeloablative conditioning and prophylaxis with a calcineurin inhibitor and mycophenolate mofetil for graft-versus-host disease.
Join us to learn about the details of this phase 3 study and explore ways that doctors can improve cord blood transplants through innovation.
with
Mitchell Horwitz, MD
Adult Blood and Marrow Transplant Program and Professor of Medicine at the Duke University Medical Center
"Improved Clinical Outcomes with Omidubicel vs. Standard Myeloablative Umbilical Cord Blood Transplantation"
Free webinar. Open to the public.
Wednesday, June 22nd, 2022 1pm ET
RECORDING NOW AVAILABLE in the Share the Science Archive
About the speaker
Mitchell Horwitz, M.D. Adult Blood and Marrow Transplant Program and Professor of Medicine at the Duke University Medical Center With over 20 years of experience, Dr. Horwitz specializes in allogeneic stem cell transplantation using umbilical cord blood grafts; allogenic stem cell transplantation for Sickle Cell Disease; prevention of acute graft versus host disease through donor stem cell graft manipulation; and improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation or third party thymus transplantation. |
Share the Science and sharing his valuable insight
on the ways to improve cord blood transplantation.
We also wish to also thank our generous sponsor and partner for this event,
WellSky Health, who continue to support cord blood
education through our “Share the Science” series.
Author
Write something about yourself. No need to be fancy, just an overview.
Archives
March 2025
December 2023
March 2023
February 2023
August 2022
June 2022
April 2022
December 2021
July 2021
June 2021
May 2021
January 2021
October 2020
September 2020
August 2020
June 2020
May 2020
March 2020
October 2019
August 2019
May 2019
April 2019
March 2019
February 2019
November 2018
August 2018
January 2018
October 2017
September 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
June 2016
March 2016
January 2016
December 2015
November 2015